Kane Biotech Inc V.KNE

Alternate Symbol(s): KNBIF

Healthcare Biotechnology

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.

TSXV:KNE - Post by User

Kane Biotech Inc

Bullboard Posts

Comment by StoneMan45on Aug 23, 2020 11:40am

92 Views

Post# 31443222

RE:DispersinB

the study was done by Prof Hedhammar (not Attana), Attana's technology was involved in the testing

A new paper has been published in MicrobiologyOpen by Prof. Hedhammar and co-workers at the
Royal Institute of Technology and Stockholm University. In this paper, recombinant spider silk was
functionalized with enzymes having antibacterial properties. This has the potential to be used as
surface coatings of surgical implants and other medical equipment to avoid bacterial colonization.
Attana’s QCM technology was employed to evaluate the immobilization of the enzymes to the spider
silk and the assembly of the spider silk

Bullboard Posts

NervGen Pharma: Proof that NVG-291 works?